All News

2071 articles, sorted by publication time.

Biomedicine · global

Multiple Sclerosis Drug Pipeline Reviewed Again as Competition Shifts From Controlling Relapses to Delaying Disability

DelveInsight’s latest market research lays out the multiple sclerosis R&D landscape anew: major pharmaceutical companies and biotech firms are still looking for treatment paths that are more precise, more convenient, and better able to address progressive disease, but the information itself remains an industry review rather than a breakthrough in new therapies.

Biotech and Pharmaceuticals · global

BetterLife Taps Syner-G to Manufacture Candidate Drug, as Early Psychedelic Drug R&D Moves Toward a Supply Chain Test

As new drugs for neuropsychiatric diseases move from concept toward the clinic, the real bottleneck is not only molecular design, but also whether medicines for human studies can be produced stably and in compliance with regulations. The partnership between BetterLife and Syner-G shows that small biotech companies are pushing R&D risk into manufacturing and quality control.